|
|
BY OUR PHARMA CORRESPONDENT
18th August,2005: The United States Patent and Trademark Office has issued to Pozen U.S. patent number 6,926,907 'Pharmaceutical Compositions for the Coordinated Delivery of NSAIDs'. This patent includes claims to pharmaceutical compositions that may contain a non-steroidal anti-inflammatory drug (NSAID) and an acid inhibitor, e.g., a proton pump inhibitor (PPI). Pozen’s PN (PPI/NSAID) combination drug candidates are covered under this patent, a company release said.
In the wake of cardiovascular safety concerns regarding the COX-2 selective NSAIDs, physicians are now recommending use of traditional non-selective NSAIDs with acid-suppressive co-therapy to prevent gastrointestinal complications. POZEN's PN drug candidates are being designed to provide this type of therapy with the added benefit of ensuring adherence with the use of the gastroprotective PPI with every dose of NSAID.
The Pozen PN tablet is designed to initially release the PPI component in the stomach and the NSAID component is released only in a lower acid environment. Pozen completed a 14-day proof-of-concept study with its drug candidate PN 100 which demonstrated that PN 100 was highly effective in preventing gastric mucosal injury compared with an NSAID alone. The results of this study have been selected for platform presentation at the Annual Scientific Meeting of the American College of Gastroenterology in November.
The PN drug candidates are being developed for the management of pain and inflammation associated with conditions such as osteoarthritis, which affects more than 20 million people in the United States, the Pozen release said.
Pozen is a pharmaceutical company developing therapeutic advancements for diseases with unmet medical needs where it can improve efficacy, safety, and/or patient convenience. Pozen has focused its efforts primarily on the development of pharmaceutical products for the treatment of migraine. The company is also exploring the development of product candidates in other pain-related therapeutic areas. Pozen has development and commercialization alliances with GlaxoSmithKline, Valeant Pharmaceuticals North America, a subsidiary of Valeant Pharmaceuticals International (formerly Xcel Pharmaceuticals, Inc.), and Nycomed Danmark ApS. The company's common stock is traded on The Nasdaq Stock Market under the symbol
"POZN".
BY OUR PHARMA CORRESPONDENT
|
